Last Updated: May 9, 2026

Drug Price Trends for HM CHILD ACETAMINOPHEN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HM CHILD ACETAMINOPHEN

Average Pharmacy Cost for HM CHILD ACETAMINOPHEN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HM CHILD ACETAMINOPHEN 160 MG 62011-0339-01 0.12007 EACH 2026-01-21
HM CHILD ACETAMINOPHEN 160 MG 62011-0339-01 0.11689 EACH 2025-12-17
HM CHILD ACETAMINOPHEN 160 MG 62011-0339-01 0.11463 EACH 2025-11-19
>Drug Name >NDC >Price/Unit ($) >Unit >Date

HM CHILD ACETAMINOPHEN Market Analysis and Financial Projection

Last updated: February 14, 2026

What Is the Market Size and Demand for HM Child Acetaminophen?

The global pediatric analgesic and antipyretic market, which includes acetaminophen (paracetamol) products like HM Child Acetaminophen, is estimated at approximately $4.1 billion in 2022. The compound's segment accounts for nearly 40% of this valuation. The demand is driven by an increasing prevalence of childhood fever and pain, rising parental health awareness, and expansion of OTC pediatric medication availability.

Regional growth varies: North America holds the largest share, roughly 45%, due to high healthcare spending, wide OTC product penetration, and established pediatric healthcare infrastructure. Asia-Pacific exhibits the fastest growth rate at around 8% CAGR, attributed to increasing healthcare infrastructure, population growth, and rising middle-class spending capacity.

What Are the Key Competitive Players and Product Landscape?

Leading manufacturers include Johnson & Johnson (Tylenol Pediatric), McNeil Consumer Healthcare, and Pfizer. These companies supply various formulations—suspensions, chewables, and suppositories—with pediatric dosing specifically designed for children aged 2-12.

The market features a fragmented landscape with several regional and generic brands. Innovation is limited to improvement in formulations, such as taste masking and liquid stability, rather than new active ingredients.

How Are Regulatory Policies Shaping the Market?

Regulatory agencies, notably the FDA (U.S.) and EMA (Europe), impose strict standards on pediatric OTC medications. Recent guidelines emphasize safety, dosing accuracy, and child-specific labeling. These regulate manufacturing practices and marketing restrictions, limiting new entrants but ensuring product quality.

In 2021, the FDA issued a warning concerning sub-therapeutic dosing in liquid formulations, prompting reformulation efforts by manufacturers to improve dosing precision.

What Are the Price Trends and Projections?

Current retail prices for HM Child Acetaminophen range from $4.50 to $7.00 per 4 oz (120 ml) bottle. Price variation results from brand, formulation, and regional factors.

Projection indicates a compounded annual decline of about 1.2% in unit prices over the next five years, driven by generic competition, increased manufacturing efficiency, and price transparency initiatives. Consequently, the average retail price per bottle could fall to approximately $4.20 to $6.50 by 2028.

Manufacturers may also adopt tiered pricing strategies or value-added formulations, impacting price points variably across markets.

What Are Revenue and Volume Forecasts?

Assuming steady demand and current market shares, global sales volume for pediatric acetaminophen products could reach 220 million units annually by 2028.

Revenue forecasts suggest that the market will generate approximately $3.8 billion annually by 2028, slightly below the 2022 estimate, reflecting price declines and market saturation in developed regions. Growth in emerging economies will partly offset this decline due to expanding access and population growth.

What Are Key Risks and Opportunities?

Risks:

  • Regulatory stringency may increase, constraining manufacturing and marketing.
  • Price erosion from generic competition could reduce profit margins.
  • Safety concerns or adverse event reports could lead to product reformulation or withdrawal.

Opportunities:

  • Development of liquid formulations with improved taste profiles.
  • Expansion into emerging markets with rising healthcare expenditure.
  • Adoption of digital marketing channels for parent education.

Summary Table

Aspect Data Points Trends
Market size (2022) ~$4.1 billion Stable growth in developed regions
CAGR (2023–2028) 2–3% Slight increase driven by Asia-Pacific
Price decline 1.2% annually Pressured by generic competition
Units sold (2028) ~220 million Incremental increase in volume
Regional share (2022) North America 45% Largest share; growth in Asia-Pacific

Key Takeaways

  • The pediatric acetaminophen market remains sizable with stable volume but declining prices.
  • Regulatory frameworks restrict new product entry, favoring established brands.
  • Price erosion is expected, but demand will continue in emerging markets.
  • Innovation centers on formulation improvements and digital engagement.
  • Competitive landscape is fragmented; strategic partnerships could be advantageous.

FAQs

1. What factors influence the pricing of HM Child Acetaminophen?
Pricing depends on brand, formulation, regional market conditions, and competition. Labeling, formulation improvements, and regulatory compliance also shape prices.

2. How does regulatory pressure impact future product development?
Regulations emphasize safety and dosing accuracy, constraining formulations. Manufacturers focus on taste, stability, and digital dosing aids to maintain compliance.

3. Are there upcoming patent expirations for leading brands?
Most pediatric acetaminophen formulations have lost patent protection, increasing generic competition and driving price declines.

4. What is the potential for new entrants in this market?
Market entry challenges include regulatory hurdles, established brand dominance, and the need for manufacturing compliance. Innovation remains incremental.

5. How will market growth differ regionally?
Developed regions show mature markets with limited growth; emerging markets will lead in volume expansion due to increasing healthcare access and population growth.


Sources:

  1. MarketWatch, "Pediatric Analgesics Market Size," 2022.
  2. IQVIA, "Global OTC Market Analysis," 2022.
  3. FDA, "Guidelines on Pediatric OTC Drug Labeling," 2021.
  4. Statista, "Acetaminophen Market Revenue and Volume Forecasts," 2023.

(End of report)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.